{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:14:05Z","timestamp":1791314045574,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13098-9","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:46:18Z","timestamp":1773971178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Virological outcomes of dolutegravir-based versus other antiretroviral regimens in people living with HIV: A systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Letebrhan","family":"Weldemhret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsehaye Asmelash","family":"Dejene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebrecherkos Teame","family":"Gebrehiwot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haftom","family":"Legese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araya Gebreyesus","family":"Wasihun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsbeha Gebreegziabxier","family":"Weldemariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"13098_CR1","volume-title":"Licence: CC BY-NC-SA 3.0 IGO","author":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","year":"2018","unstructured":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2018. http:\/\/www.who.int\/hiv\/pub\/guidelines\/ARV2018update\/en\/. WHO\/CDS\/HIV\/18.51."},{"key":"13098_CR2","unstructured":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. Geneva: World Health Organization. 2018 (WHO\/CDS\/HIV\/18.18). Licence: CC BY-NC-SA 3.0 IGO."},{"key":"13098_CR3","unstructured":"World Health Organization (WHO). HIV data and statistics. 2024. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stisprogrammes\/hiv\/strategic-information\/hiv-data-and-statistics"},{"key":"13098_CR4","unstructured":"World Health Organizations. The role of HIV viral suppression in improving individual health and reducing transmission: policy brief. Geneva: World Health Organization; 22 July 2023| Policy brief."},{"key":"13098_CR5","volume-title":"and second-line antiretroviral regimens","author":"Update of recommendations on first","year":"2019","unstructured":"Update of recommendations on first-. and second-line antiretroviral regimens. Geneva, Switzerland: WHO\/CDS\/HIV\/1915; 2019."},{"key":"13098_CR6","unstructured":"Federal Ministry of Health of Ethiopia. National consolidated guideline for comprehensive HIV prevention, care and treatment August, 2018."},{"key":"13098_CR7","unstructured":"U.S. Department of Health and Human Services. Guidance for Industry: Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM355128.pdf; 2013. Contract No.: Accessed on 28th October, 2018."},{"key":"13098_CR8","unstructured":"WHO, HIV Drug Resistance, World Health Organization. Report 2017; Geneve, Switzerland; Elsevier Ltd.\/Inc.\/BV: Cambridge, MA, USA, 2017; ISBN 8651085917763."},{"key":"13098_CR9","unstructured":"WHO. Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring - news release, 16 July 2021."},{"issue":"28","key":"13098_CR10","doi-asserted-by":"publisher","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","volume":"16","author":"S Kanters","year":"2020","unstructured":"Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400\u00a0mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine. 2020;16(28):100573. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100573. CrossRef Full Text | Google Scholar.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"13098_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4269\/ajtmh.24-0249","volume":"112","author":"N Shah","year":"2024","unstructured":"Shah N, Crowell TA, Hern J, Anyebe V, Bahemana E, Kibuuka H, et al. The Transformative Impact of the African Cohort Study (AFRICOS) Toward Reaching HIV 95-95-95 Goals in Sub-Saharan Africa. Am J Trop Med Hyg. 2024;112(1):45\u201355. https:\/\/doi.org\/10.4269\/ajtmh.24-0249.","journal-title":"Am J Trop Med Hyg"},{"key":"13098_CR12","unstructured":"World Health Organization. New report documents increase in HIV drug resistance to dolutegravir. 5 March 2024; News release."},{"key":"13098_CR13","doi-asserted-by":"publisher","first-page":"1253661","DOI":"10.3389\/fviro.2023.1253661","volume":"3","author":"D Kamori","year":"2023","unstructured":"Kamori D, Barabona G. Dolutegravir resistance in sub-Saharan Africa: should resource-limited settings be concerned for future treatment? Front. Virol. 2023;3:1253661. https:\/\/doi.org\/10.3389\/fviro.2023.1253661.","journal-title":"Virol"},{"key":"13098_CR14","unstructured":"HHS Panel on Antiretroviral Guidelines for Adults and Adolescents\u2014A Working Group of the NIH Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIVS. Last Update: September 12, 2024. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"key":"13098_CR15","doi-asserted-by":"crossref","unstructured":"Semengue ENJ, Fokam J, Etame NK, Molimbou E, Chenwi CA, Takou D et al. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model. Viruses 2023, 15, 18. https:\/\/doi.org\/10.3390\/v15010018. https:\/\/www.mdpi.com\/journal\/viruses","DOI":"10.3390\/v15010018"},{"key":"13098_CR16","doi-asserted-by":"publisher","unstructured":"Matthew J, Page, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71. (Published 29 March 2021).","DOI":"10.1136\/bmj.n71"},{"key":"13098_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"13098_CR18","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): Wiley; 2019.","edition":"2"},{"issue":"6","key":"13098_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.295.6.676","volume":"295","author":"JL Peters","year":"2006","unstructured":"Peters JL, Sutton AJ, Jones DR, KAbrams KR, Rushton L. Comparison of Two Methodsto Detect Publication Bias in Meta-analysis. JAMA. 2006;295(6):676\u201380. https:\/\/doi.org\/10.1001\/jama.295.6.676.","journal-title":"JAMA"},{"issue":"2","key":"13098_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111. https:\/\/doi.org\/10.1002\/jrsm.12. Epub 2010 Nov 21.","journal-title":"Res Synth Methods"},{"issue":"11","key":"13098_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"key":"13098_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"32","author":"J Higgins","year":"2003","unstructured":"Higgins J, Thompson S, Deeks J, Altman DTI. Measuring inconsistency in meta-analyses. BMJ. 2003;32:557\u201360.","journal-title":"BMJ"},{"issue":"2","key":"13098_CR23","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/S2352-3018(22)00261-4","volume":"10","author":"C Orkin","year":"2023","unstructured":"Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al. Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a three- or four-drug regimen for maintenance of virological suppression in adults with HIV-1 (SALSA): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2023;10(2):e69\u201379. https:\/\/doi.org\/10.1016\/S2352-3018(22)00261-4.","journal-title":"Lancet HIV"},{"key":"13098_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40199-023-00470-2","volume":"31","author":"G Alavian","year":"2023","unstructured":"Alavian G, Abbasian L, Khalili H, Alinaghi SAS, Hasannezhad M, Ashtiani MF, Manshadi SD. Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial. DARU J Pharm Sci. 2023;31:145\u201353. https:\/\/doi.org\/10.1007\/s40199-023-00470-2.","journal-title":"DARU J Pharm Sci"},{"issue":"19","key":"13098_CR25","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Guti\u00e9rrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807\u201318.","journal-title":"N Engl J Med"},{"issue":"6","key":"13098_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"O Osiyemi","year":"2022","unstructured":"Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, Wyen C, Ait-Khaled MA, et al. Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. Clin Infect Dis. 2022;75(6):975\u201386. https:\/\/doi.org\/10.1093\/cid\/ciac036.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"13098_CR27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, et al. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir\/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023;76(4):720\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac130.","journal-title":"Clin Infect Dis"},{"key":"13098_CR28","doi-asserted-by":"crossref","unstructured":"Ryan P, Blanco JL, Masia M, Fraile LG, Crusells MJ, Domingo P, Adrian Curran A. at al. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. The Lancet HIV. 2025;12(7):e473-e484. doi: 1Lancet HIV.(25)00105-5. Epub 2025 Jun 7.","DOI":"10.1016\/S2352-3018(25)00105-5"},{"key":"13098_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019;381:803\u201315. DOI: 10.1056\/NEJMoa1902824;381 9.","journal-title":"N Engl J Med"},{"issue":"9","key":"13098_CR30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"C Kouanfack","year":"2019","unstructured":"Kouanfack C, Etame MM, Bassega PO, Duvernay SE, Leroy S, Boyer S, Peeters M, et al. Epub 2019 Jul 24.Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019;381(9):816\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1904340. Epub 2019 Jul 24.","journal-title":"N Engl J Med"},{"issue":"10","key":"13098_CR31","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","volume":"7","author":"A Calmy","year":"2020","unstructured":"Calmy A, Sanchez TT, Kouanfack C, Etame MM, Leroy S, Perrineau S, Wandji ML, Tata DT, Bassega PO, Bwenda TA, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020;7(10):e677\u201387. https:\/\/doi.org\/10.1016\/S2352-3018(20)30238-1.","journal-title":"Lancet HIV"},{"issue":"5","key":"13098_CR32","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(20)30050-3","volume":"7","author":"K Kintu","year":"2020","unstructured":"Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, Seden K, Eva Maria Hodel EM, Chen T. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Lancet HIV. 2020;7(5):e332\u20139. https:\/\/doi.org\/10.1016\/S2352-3018(20)30050-3.","journal-title":"Lancet HIV"},{"issue":"10","key":"13098_CR33","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"WDF Venter","year":"2020","unstructured":"Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666\u201376. https:\/\/doi.org\/10.1016\/S2352-3018(20)30241-1.","journal-title":"Lancet HIV"},{"issue":"8","key":"13098_CR34","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Sogorb JP, et al. Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clin Infect Dis. 2020;71(8):1920\u20139. https:\/\/doi.org\/10.1093\/cid\/ciz1243.","journal-title":"Clin Infect Dis"},{"key":"13098_CR35","doi-asserted-by":"crossref","unstructured":"Molina JM, Clotet B, Lunzen JV, Lazzarin A, Cavassini M, Henry K, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults withHIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV Volume. April 2015;2(4):e127\u201336.","DOI":"10.1016\/S2352-3018(15)00027-2"},{"key":"13098_CR36","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 an 96week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735\u201343.","journal-title":"Lancet"},{"issue":"8","key":"13098_CR37","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(21)00100-4","volume":"8","author":"J Rojas","year":"2021","unstructured":"Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, et al. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV. 2021;8(8):e463\u201373. https:\/\/doi.org\/10.1016\/S2352-3018(21)00100-4.","journal-title":"Lancet HIV"},{"key":"13098_CR38","doi-asserted-by":"crossref","unstructured":"Clotet B, Feinberg J, Lunzen JV, Khuong-Josses MA, Andrea Antinori MD, Irina Dumitru. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48-week results from the randomised open-label phase 3b study. Lancet HIV., 2014 28 June;383(9936):p2222-2231.","DOI":"10.1016\/S0140-6736(14)60084-2"},{"issue":"7","key":"13098_CR39","doi-asserted-by":"crossref","first-page":"e0219995","DOI":"10.1371\/journal.pone.0219995","volume":"14","author":"A Borghetti","year":"2019","unstructured":"Borghetti A, Celesia BM, Baldonero E, Di Giambenedetto S, Forbici F, Maggi P, et al. Dolutegravir-based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis. PLoS ONE. 2019;14(7):e0219995.","journal-title":"PLoS ONE"},{"issue":"11","key":"13098_CR40","doi-asserted-by":"publisher","first-page":"e1003421","DOI":"10.1371\/journal.pmed.1003421","volume":"17","author":"D Sculier","year":"2020","unstructured":"Sculier D, Wandeler G, Yerly S, Marinosci A, Stoeckle M, Bernasconi E, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL\u2019HIV trial. PLoS Med. 2020;17(11):e1003421. https:\/\/doi.org\/10.1371\/journal.pmed.1003421.","journal-title":"PLoS Med"},{"issue":"7","key":"13098_CR41","first-page":"545","volume":"22","author":"F Maggiolo","year":"2021","unstructured":"Maggiolo F, De Luca A, Castagna A, Rusconi S, Galli L, Di Biagio A, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic review and real-world meta-analysis. HIV Med. 2021;22(7):545\u201358.","journal-title":"HIV Med"},{"key":"13098_CR42","unstructured":"Soriano-Vazquez L, Caby F, Minga A, Toure-Kane C, Sculier D, Ndiaye B et al. Dolutegravir plus lamivudine as a simplification strategy maintains viral suppression in virologically suppressed adults, with low rates of virological failure (ANRS 167 LAMIDOL and ASPIRE trials). Lancet HIV. 2021;8(5)."},{"key":"13098_CR43","unstructured":"Soriano-Vazquez L, Caby F, Minga A, Toure-Kane C, Sculier D, Ndiaye B, et al. Dolutegravir plus lamivudine as a simplification strategy maintains viral suppression in virologically suppressed adults, with low rates of virological failure. Lancet HIV. 2021;8(5)."},{"key":"13098_CR44","first-page":"3975","volume":"19","author":"A Hill","year":"2019","unstructured":"Hill A, Sawyer AW, Boffito M, Pozniak A, Nelson M, et al. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naive patients with HIV-1: a systematic review and network meta-analysis. BMC Infect Dis. 2019;19:3975.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"13098_CR45","first-page":"1985","volume":"71","author":"R Zash","year":"2020","unstructured":"Zash R, Holmes L, Diseko M, Jacobson DL, Mayondi G, Mmalane M, et al. Effectiveness of dolutegravir-based ART in patients with high baseline viral load: evidence from Botswana Tsepamo study, 48- and 96-week analysis. Clin Infect Dis. 2020;71(8):1985\u201394.","journal-title":"Clin Infect Dis"},{"key":"13098_CR46","doi-asserted-by":"crossref","unstructured":"Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13(7):797\u2013804. Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10357378","DOI":"10.1097\/00002030-199905070-00008"},{"key":"13098_CR47","doi-asserted-by":"crossref","unstructured":"Sonya J, Snedecor M, Radford D 2. Kratochvil1, Richard Grove3 and Yogesh S. Punekar2. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infectious Diseases. 2019;19:484.","DOI":"10.1186\/s12879-019-3975-6"},{"key":"13098_CR48","doi-asserted-by":"publisher","unstructured":"Mario CID, Saverio G, Parisi. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and metanalysis. PLoS ONE 14(9): e0222229. https:\/\/doi.org\/10.1371\/journal.pone.0222229","DOI":"10.1371\/journal.pone.0222229"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13098-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13098-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13098-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:12:26Z","timestamp":1777345946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13098-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13098"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13098-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves no direct patient contact, as it is based on previously conducted primary studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"847"}}